Aspirin vs low molecular weight heparin
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes onlyRR 1 [0.06, 15.81]2 studies · 781 participantsVery low
- Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents 2021 · Cochrane Headline outcomes onlyRR 1 [0.06, 15.89]1 study · 440 participantsVery low